This article needs additional citations for verification. (November 2019) (Learn how and when to remove this template message)
Moletest was initially created as a UK-based application set up in September 2010. On launch it was the world's first online remote mole screening service for the detection of non-melanoma ( e.g. Basal cell carcinoma, Squamous cell carcinoma) and melanoma skin cancers in moles. The firm developed a unique image processing technique to assess photographic images of lesions (melanocytic nevus) against known case results – providing a ‘traffic light’ based evaluation where green is a ‘normal’ lesion, amber a ‘borderline’ lesion with potentially unpredictable biological behaviour, and red a potentially ‘cancerous’ one. The company has since evolved this initial concept into a new product, nomela®. Unlike the earlier on-line system nomela® works on iOS devices and initial testing has been on the iPad. It uses a disparate selection of the earlier algorithms where each has a distinct range for melanoma. These particular algorithms have been chosen because they provide a window onto the cellular world using a close-up digital image. The rationale for nomela® is that it can safely identify, almost instantaneously, no evidence of melanoma rather than specific diagnosis of disease. The benefits arising include a 50% + reduction in referrals from Primary to Secondary Care, generating patient management efficiencies and substantial cost savings to Health Institutions and Health Insurance companies worldwide.
Moletest Limited is incorporated in Guernsey. The main licensed UK company is Moletest (Scotland) Limited trading as Nomela®.